UTHealth-Houston
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gupta, Rajesh
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
GLUE, NCT05038319: SAFETY AND EFFICACY OF ENDOSCOPIC CONVENTIONAL CYANOACRYLATE VS EUS-GUIDED COIL PLUS CYANOACRYLATE TECHNIQUE IN THE TREATMENT OF GASTRIC VARICES: A RANDOMIZED CONTROLLED TRIAL

Recruiting
N/A
34
RoW
EUS
Asian Institute of Gastroenterology, India
Glue; Dependence
12/21
05/22
BFMSP, NCT05632900: COMPARISON OF OUTCOMES OF BI-FLANGED METAL STENT ALONE VERSUS BI-FLANGED METAL STENT WITH CO-AXIAL PLASTIC STENT FOR DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS - A PROSPECTIVE RANDOMISED CONTROLLED STUDY.

Completed
N/A
76
RoW
Endoscopic ultrasound guided drainage of walled off pancreatic necrosis
Asian Institute of Gastroenterology, India
ENDOSCOPIC ULTRASONOGRAPHY
10/22
12/22
NCT05822635: SpyGlass Surgical Study

Completed
N/A
34
US, RoW
SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System
Boston Scientific Corporation
Pancreatic Diseases, Bile Duct Diseases, Hepatic Disease
12/24
01/25
Jemelka, James Jim
NCT05285891: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Recruiting
4
123
US
Ocrelizumab, Ocrevus, Placebo for Ocrelizumab
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence (ACE), Rho Federal Systems Division, Inc., Genentech, Inc.
Multiple Sclerosis
08/28
08/28
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30

Download Options